Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) recorded a decline in its consolidated attributable profit to 12.5 billion Indian rupees in the fiscal second quarter ended Sept. 30 against 14.8 billion rupees a year ago.
Earnings per share contracted to 15.05 rupees compared with a year-ago figure of 17.76 rupees, according to a filing to the stock exchanges on Tuesday by the pharmaceutical company.
Revenue from operations in fiscal Q2 increased to 80.2 billion rupees from 68.8 billion rupees a year earlier.
Shares of the company were up over 1% in recent trade.
Price (INR): ₹1318.10, Change: ₹+15, Percent Change: +1.16%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。